Ceribell (NASDAQ: CBLL) saw its stock price surge 5.04% in after-hours trading on Tuesday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.
The medical technology company reported quarterly revenue of $21.2 million, surpassing analyst expectations of $20.528 million by 3.27%. Ceribell also posted a narrower-than-expected loss per share of $(0.38), beating the consensus estimate of $(0.40) by 4.52%.
Adding to the positive sentiment, Ceribell raised its 2025 revenue guidance to a range of $85-$88 million, signaling strong confidence in its growth trajectory. This combination of better-than-expected current performance and improved future outlook appears to be driving investor enthusiasm, resulting in the significant after-hours stock price increase.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。